Omapatrilat for the management of heart failure and hypertension.
(1) Omapatrilat, first in a new class of cardiovascular drugs called vasopeptidase inhibitors, is under evaluation for the management of hypertension and heart failure. (2) Several small trials have demonstrated the efficacy and tolerability of once-daily omapatrilat in the treatment of mild to moderate hypertension. Efficacy data from one medium-sized trial have demonstrated a benefit comparable to lisinopril in the treatment of systolic heart failure. (2) The benefits and risks of omapatrilat as compared to ACE inhibitors are under evaluation and could affect future clinical therapy guidelines for managing hypertension and heart failure.
Husereau
D R
DR
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017706:Lisinopril; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical; D013841:Thiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D011725:Pyridines; D013841:Thiazepines; D017706:Lisinopril